- Donald Abrams, MD, Former Chief of Hematology-Oncology, Zuckerberg San Francisco General Hospital, Professor of Clinical Medicine, University of California, San Francisco
Jefferson’s Center will fill the gap and provide much needed comprehensive institutional leadership in medical cannabis education and clinical research. I am pleased to be part of the effort.
Donald Abrams, MD
Former Chief, Hematology-Oncology
Zuckerberg San Francisco General Hospital
Professor of Clinical Medicine
University of California, San Francisco
Marcel Bonn-Miller, PhD
Research Director, Lambert Center
David Casarett, MD, MA
Professor of Medicine, Duke University School of Medicine
Chief of Palliative Care Services
Duke University Health System
Richard C. Dart, MD, PhD
Rocky Mountain Drug and Poison Control Center
Mahmoud A. ElSohly, PhD
Research Professor in the Research Institute of Pharmaceutical Sciences
Pharmaceutical Product Development
The University of Mississippi
Larry I. Good, MD
Assistant Clinical Professor
School of Medicine
State University of New York, Stony Brook
Staci Gruber, PhD
Director, Cognitive and Clinical Neuroimaging Core
Director, Marijuana Investigations for Neuroscientific Discovery (MIND)
Manuel Guzmán, PhD
Professor of Biochemistry & Molecular Biology
Molecular Biology/Endocannabinoid System
University of Madrid
Kevin Hill, MD
Assistant Professor of Psychiatry, Harvard Medical School, Director of Addiction Psychiatry
Beth Isreal Deaconess Medical Center
Boston, MA 02215
Marilyn A. Huestis, PhD
President, Huestis & Smith Toxicology, LLC
Consultant, Department of Transportation
Senior Scientific Advisor, NMS Labs
Lumír Ondrej Hanuš, PhD
Eric Marsh, MD, PhD
Department of Neurology
Children's Hospital of Philadelphia
Daniel Monti, MD, MBA
Executive and Medical Director
Myrna Brind Center of Integrative Medicine
Thomas Jefferson University
Suzanne Sisley, MD
Asst. Professor, Life Sciences
Colorado State University
Nancy Skinner, RN-BC, CCM
Past President, Case Management Society of America
Adjunct Faculty, Case Management
University of Southern Indiana
Ryan Vandrey, PhD
Associate Professor, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine.
Eugene R. Viscusi, MD
Director, Acute Pain Management
Department of Anesthesiology
Thomas Jefferson University
President-Elect, American Society of Regional Anesthesia
Mark Ware, MBBS, MRCP (UK), MSc
Director of Clinical Research, Alan Edwards Pain Management Unit
McGill University Health Centre
Up-to-date Steering Committee Article Citations
Ibrahim EA, Wang M., Radwan MM..., Elsohly MA. Analysis of Terpenes in Cannabis sativa L Using GC/MS: Method Development, Validation, and Application. Planta Medica. 2019; 85(5): 431-438.
Schuetze P, Zhao J, Eiden RD…, Huestis MA. Prenatal exposure to tobacco and marijuana and child autonomic regulation and reactivity: An analysis of indirect pathways via maternal psychopathology and parenting. Developmental Psychobiology. 2019; article in press. DOI: 10.1002/dev.21844
Huestis MA, Blount BC, Milan DF, et al. Correlation of creatinine- and specific gravity-normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users. 2019; article in press. DOI: 10.1002/dta.2576
Aguareles J, Paraíso-Luna J, Palomares B, Bajo-Grañeras R, Navarrete C, Ruiz-Calvo A,…Guzman M, et al. Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration. Translational Neurodegen 2019; 8. DOI: 10.1186/s40035-019-0148-x
Bonn-Miller MO, ElSohly MA, Loflin MJE, Chandra S, Vandrey R. Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches. Int Rev Psychiatry. 2018 Jun;30(3):277-284. PMID: 30179534
Vandrey R. The cannabis conundrum: steering policy and medicine with insufficient data. Int Rev Psychiatry. 2018 Jun;30(3):181-182. PMID: 30179536
Hill KP, Palastro MD, George T. Therapeutic cannabis use in 2018: where do we stand? Lancet Psychiatry. 2019; 6:88-89.
Guzman M. Cannabis for the management of cancer symptoms: THC version 2.0? Cannabis Cannabinoid Res. 2018; 3: 117-119. The question of ‘‘what would be the best cannabis chemotype and, in particular, THC/CBD ratio for each particular patient in each particular pathological status?’’ remains a pending question in the field. …A multifactorial approach …could be considered from three complementary levels: (1) Pre-clinical studies,… (2) Controlled clinical trials, …and (3) Observational studies with different chemotypes, preparations, and delivery procedures…
Barrett FS, Schlienz NJ, Lembeck N, …Vandrey R. "Hallucinations" following acute cannabis dosing: A Case report and comparison to other hallucinogenic drugs. Cannabis Cannabinoid Res. 2018; 3: 85-93. Acute cannabis exposure in a healthy adult male resulted in self-reported hallucinations that rated high in magnitude on several subscales of the HRS. However, the hallucinatory experience in this case was qualitatively different than that typically experienced by participants receiving classic and atypical hallucinogens, suggesting that the hallucinatory effects of cannabis may have a unique pharmacological mechanism of action.
Balneaves LG, Alraja A, Ziamianski D,…Ware M. A National needs assessment of Canadian nurse practitioners regarding cannabis for therapeutic purposes. Cannabis Cannabinoid Res. 2018; 3: 66-73. Nursing regulatory organizations, in partnership with academic institutions and government agencies, must work toward the development of educational and clinical competencies specific to cannabis for therapeutic purposes (CTP). Tailored education programs are needed to address the knowledge gaps held by NPs and the clinical barriers they face to including CTP as part of their care.
Gallily R, Yekhtin Z, Hanuš LO. The Anti-inflammatory properties of terpenoids from cannabis. Cannabis Cannabinoid Res. 2018;3(1):282-290. doi: 10.1089/can.2018.0014. The different Cannabis chemotypes showed distinct compositions of terpenoids. The terpenoid-rich essential oils exert anti-inflammatory and antinociceptive activities in vitro and in vivo, which vary according to their composition. None of the essential oils was as effective as purified CBD. In contrast to CBD that exerts prolonged immunosuppression and might be used in chronic inflammation, the terpenoids showed only a transient immunosuppression and might thus be used to relieve acute inflammation.
Lee DC, Schlienz NJ, Peters EN, …, Vandrey R. Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder. Drug Alcohol Depend. 2019; 194:500-517.
Carlier J, Wohlfarth A, Salmeron BD, …, Huestis MA, Baumann MH. Pharmacodynamic effects, pharmacokinetics, and metabolism of the synthetic cannabinoid AM-2201 in male rats. J Pharmacol Exp Ther. 2018; 367: 543-550.
deShazo RD, Parker SB, Williams D,… Elsohly M, et al. Marijuana's effects on brain structure and function: What do we know and what should we do? A Brief review and commentary. Am J Med. 2018; article in press. DOI: 10.1016/j.amjmed.2018.09.006
Schlienz NJ, Cone EJ, Herrmann ES, (...), Vandrey R. Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults. J Anal Toxicol. 2018; 42:232-247.
Abrams DI. The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 2018 Mar;49:7-11.
Bonn-Miller MO, ElSohly MA, Loflin, MJE, Chandra S, Vandrey R. Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches. Int Rev Psychiatry. 2018; 30:277-284.
Vandry R. The cannabis conundrum: steering policy and medicine with insufficient data. Int Rev Psychiatry. 2018; 30: 181-182.
López-Valero I, Torres S, Salazar-Roa, M,…Guzman M, et al. Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma. Biochem Pharmacol. 2018. In press. DOI: 10.1016/j.bcp.2018.08.023
Godleski SA, Shisler S, Eiden, RD, Huestis MA. Co-use of tobacco and marijuana during pregnancy: Pathways to externalizing behavior problems in early childhood. Neurotoxicol Teratol. 2018; 69: 39-48. Use and co-use of tobacco and marijuana during pregnancy are associated with the development of social, cognitive, and behavioral problems for infants and children. Co-use during pregnancy and continued maternal tobacco and marijuana use from infancy through early childhood were investigated.
Eiden RD,… Huestis MA. Prenatal exposure to tobacco and cannabis: Effects on autonomic and emotion regulation. Neurotox Teratol. 2018; 68:47-56.
Carlier J,…Huestis MA. Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. J Pharmaceutical Biomed Anal. 2018; 157:27-35.
Hill KP, Saxon AJ. The role of cannabis legalization in the opioid crisis. JAMA Intern Med. 2018; 178: 679-80.
Conchiero M, Huestis MA. Drug exposure during pregnancy: Analytical methods and toxicological findings. Bioanalysis. 2018; 10:587-606.
Schelienz NJ, …Vandrey R. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. Drug Alcohol Depend. 2018; 187:254-60.
Sempio C,… Huestis MA. Optimization of recombinant β-glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. Drug Test Anal. 2018; 10:518-529.
DePhilippis D, Petry NM, Bonn-Miller MO, et al. The national implementation of Contingency Management (CM) in the Department of Veterans Affairs: Attendance at CM sessions and substance use outcomes. Drug Alcohol Depend. 2018; 185:367-73.
Logan BK, … Huestis MA. Recommendations for toxicological investigation of drug-impaired driving and motor vehicle fatalities-2017 update. J Analytic Toxicol. 2018; 42:63-68.
George TP, Hill KP, Vaccarino FJ. Cannabis legalization and psychiatric disorders: Caveat “Hemp-tor”. Can J Psychiatr. 2018; https://doi.org/10.1177/0706743718762387.
Abrams, Donald I. (2018) "The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report, European Journal of Internal Medicine,
Vol. 49 Available at: https://doi.org/10.1016/j.ejim.2018.01.003.
Galal Osman A, Elokely KM, Yadav VK,… ElSohly MA. Bioactive products from singlet oxygen photooxygenation of cannabinoids. Eur J Medicinal Chem. 2018; 143:983-96.
Mateo Y, Johnson KA, Covey DP, … Guzman M, et al. Endocannabinoid actions on cortical terminals orchestrate local modulation of dopamine release in the nucleus accumbens. Neuron. 2017; 96:1112-1126.e5
Hill KP, Palastro MD. Medical cannabis for the treatment of chronic pain and other disorders: Misconceptions and facts. Pol Arch Intern Med. 2017; 127: 785-789.
Hill KP, Palastro MD, Gruber SA et al. Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study. Am J Addict. 2017; 26:795-801.
Raslan AE, Radwan MM,Ahmed SA,…ElSohly MA. Monanchoramides A–D, ceramides from the marine sponge Monanchora clathrata with cytotoxic activity. Phytochem Lett. 2018; 23:83-89.
Bonn-Miller MO, Loflin MJ, Thomas BF,… Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017; 318:718-9.
Díaz-Alonso J, De Salas-Quiroga A, Paraíso-Luna J,… Guzmán, M, et al. Loss of Cannabinoid CB1 Receptors Induces Cortical Migration Malformations and Increases Seizure Susceptibility. Cerebral Cortex.2017; 27:5303-17.